Chembio Diagnostics Inc  

(Public, NASDAQ:CEMI)   Watch this stock  
Find more results for CEMI
4.61
-0.06 (-1.28%)
May 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.59 - 4.67
52 week 2.83 - 5.20
Open 4.67
Vol / Avg. 11,091.00/14,336.00
Mkt cap 44.76M
P/E     -
Div/yield     -
EPS -0.12
Shares 9.63M
Beta 0.29
Inst. own 19%
May 7, 2015
Q1 2015 Chembio Diagnostics Inc Earnings Call - 10:00AM EDT - Add to calendar
May 7, 2015
Q1 2015 Chembio Diagnostics Inc Earnings Release - 9:30AM EDT - Add to calendar
Mar 5, 2015
Q4 2014 Chembio Diagnostics Inc Earnings Call - Webcast
Mar 5, 2015
Q4 2014 Chembio Diagnostics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -6.99% -4.11%
Operating margin -9.47% -5.61%
EBITD margin - -2.93%
Return on average assets -8.13% -4.60%
Return on average equity -9.99% -5.70%
Employees 166 -
CDP Score - -

Address

3661 Horseblock Rd
MEDFORD, NY 11763-2215
United States - Map
+1-631-9241135 (Phone)
+1-775-8849383 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Chembio Diagnostics, Inc. develops, manufactures, markets and licenses rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's main products available are four rapid tests for the detection of HIV 1/2 antibodies, two rapid tests for the detection of syphilis antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. Three of the HIV 1/2 rapid tests employ in-licensed and lateral flow technologies, can be used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format, and a barrel format. The Company�s fourth HIV 1/2 rapid antibody detection test incorporates its Dual Path Platform (DPP) POCT technology.

Officers and directors

John J. Sperzel III President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Richard J. Larkin Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Sharon Klugewicz Chief Operating Officer
Age: 47
Bio & Compensation  - Reuters
Javan Esfandiari Sr. VP - Research and Development
Age: 48
Bio & Compensation  - Reuters
Tom Ippolito Vice President - Regulatory Affairs, Quality Assurance and Quality Control
Age: 52
Bio & Compensation  - Reuters
Paul Lambotte Ph.D. Vice President - Product Development
Age: 63
Bio & Compensation  - Reuters
Michael K. Steele Vice President of Sales and Marketing
Age: 48
Bio & Compensation  - Reuters
Katherine L. Davis Non-Executive Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Barbara A. DeBuono M.D., M.P.H. Independent Director
Age: 59
Bio & Compensation  - Reuters
Peter T. Kissinger Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters